Tango Therapeutics (TNGX) Goldman Sachs 45th Annual Global Healthcare Conference summary

Leadership and company background

• CEO has a strong background in academic oncology and pharma, with expertise in breast cancer genetics and early oncology drug development.

• The company was named to reflect the duality of target and genetic abnormality, aligning with the synthetic lethality approach.

• Chose to go public via a SPAC with a shareholder base of long-term biotech investors, resulting in low redemption rates and high ownership concentration.

• 80% of shares are held by the top 10 investors, contributing to low liquidity but strong investor alignment.

Clinical pipeline and scientific strategy

• Focused on PRMT5 inhibitors targeting MTAP-deleted cancers, leveraging synthetic lethality for selective tumor targeting.

• Two lead assets, TNG908 (brain-penetrant) and TNG462 (more potent, MTAP-selective), are both in dose expansion phases, with simultaneous clinical updates expected in the second half of the year.

• TNG908 completed dose escalation with 66 patients, now expanding at 600 mg BID; TNG462 enrollment benefited from increased awareness and selectivity.

• Both assets show full SDMA suppression, but biomarker reduction alone does not guarantee clinical efficacy.

• TNG462 has demonstrated on-target toxicity (thrombocytopenia, anemia) and a favorable tolerability profile compared to competitors.

Industry context and competitive landscape

• PRMT5 inhibitors have generated industry buzz, with recent competitor data validating the approach and boosting sector confidence.

• Durability of response in early data is promising, with some patients experiencing near-complete responses for up to a year.

• Combination strategies are prioritized, especially with KRAS and CDK4/6 inhibitors, to enhance efficacy and address tumor resistance.

• Overlapping toxicities in combinations are a concern, requiring careful sequencing and regimen design.